By 2025, only about 19% of companies with 200 or more workers were covering GLP-1s for weight loss
Its only for premenopausal women with no history of heart disease
Whereas GLP-1 decreases plasma glucose levels by exerting insulinotropic effects, glucagon stimulates hyperglycemia by enhancing hepatic glucose output
Shares of Zealand Pharma dropped by a record 35% the day after the announcement, while Roche fell around 3%
What we need to do is raise our cells glutathione levels to increase that powerful resistance against toxins, painful inflammation, digestive issues, skin issues, mobility issues, macular degeneration, heart disease, cancer virtually all the illnesses we fear today